Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

Reuters Staff  |  April 27, 2020

(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…

3 Ways to Advance the Med-Peds Role in Rheumatology

Carina Stanton  |  April 27, 2020

Research into training and careers for Med-Peds—internal medicine-pediatrics trained rheumatologists–will help pinpoint how this unique specialty can support patient needs and address rheumatology workforce shortages…

Locum Tenens as a Resource for Practices During the COVID-19 Outbreak

From the College  |  April 27, 2020

As the number of COVID-19 cases continues to rise in the U.S., the fast spread of the virus is causing gaps in practice staffing, and patient influx will likely increase, leaving systems needing more providers. The use of locum tenens physicians can help practice fill gaps at your organization caused by COVID-19. Below we offer…

Systemic Sclerosis Patients May Benefit from Targeted Stroke Screening

Lara C. Pullen, PhD  |  April 27, 2020

Patients with systemic sclerosis (SSc) may benefit from targeted stroke screening or prevention therapies. A recent study revealed SSc may be independently associated with stroke, finding the risk of stroke was 20–30% higher in SSc patients than healthy controls…

Reimbursement Tips: Telemedicine & Coding in the Time of COVID-19

Kimberly Retzlaff  |  April 24, 2020

Humans may fear change as a general rule, but we’re adaptable when we need to be. In this era of COVID-19 and social distancing, medical practices and payers are adapting to an increased use of telemedicine, which enables providers to see their patients without being in a room with them. To cope, the Centers for…

The author in her home office.

On Pandemics & Uncertainty: One Rheumatologist’s Story

Belinda Birnbaum, MD  |  April 24, 2020

As the mystery solvers, we are supposed to be comfortable with the unknown, but how does that translate when COVID-19 hits home? A rheumatologist contracts COVID-19.

Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares

Carina Stanton  |  April 21, 2020

A study found resident memory T cells may mediate inflammatory arthritis and trigger flares in specific joints, suggesting local depletion of these cells could be a therapeutic strategy…

Autoimmunity on the Rise in the U.S.

Marilynn Larkin  |  April 21, 2020

NEW YORK (Reuters Health)—The prevalence of antinuclear antibodies (ANA) in the blood of U.S. adolescents and adults has increased over the past 30 years, signaling a rise in autoimmunity, researchers say. “It is not known if these same increases are occurring in other parts of the world, but because ANA are associated with many autoimmune…

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

Lisa Rapaport  |  April 21, 2020

(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or…

Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

Will Boggs, MD  |  April 21, 2020

NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,…

  • « Previous Page
  • 1
  • …
  • 205
  • 206
  • 207
  • 208
  • 209
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences